ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Philadelphia, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Philadelphia, PA, USA:

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma....

Active, not recruiting
Multiple Myeloma
Drug: daratumumab

Phase 2

Janssen (J&J Innovative Medicine)

Philadelphia, Pennsylvania, United States and 56 other locations

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma...

Enrolling
Multiple Myeloma
Myeloma
Drug: Bendamustine
Drug: FT576 (Allogenic CAR NK cells with BCMA expression)

Phase 1

Fate Therapeutics
Fate Therapeutics

Newark, Delaware, United States and 13 other locations

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Active, not recruiting
Multiple Myeloma
Drug: Venetoclax
Drug: Dexamethasone

Phase 2

AbbVie
AbbVie

Philadelphia, Pennsylvania, United States and 31 other locations

CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: PHE885

Phase 2

Novartis
Novartis

Philadelphia, Pennsylvania, United States and 37 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Carfilzomib

Phase 3

Celgene
Celgene

Philadelphia, Pennsylvania, United States and 59 other locations

patients responding to first- or second-line therapy for high-risk multiple myeloma. The regimen evaluated in this study is based o...

Active, not recruiting
Multiple Myeloma
Combination Product: CART BCMA or CART BCMA + huCART19
Combination Product: BCMA CART + huCART19

Phase 1

University of Pennsylvania
University of Pennsylvania

Philadelphia, Pennsylvania, United States

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)

Bethlehem, Pennsylvania, United States and 211 other locations

is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: CTX120

Phase 1

CRISPR Therapeutics

Philadelphia, Pennsylvania, United States and 9 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Philadelphia, Pennsylvania, United States and 126 other locations

doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment o ...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab

Phase 2

Pfizer
Pfizer

Philadelphia, Pennsylvania, United States of America and 41 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems